Improving Effective Basal Insulin Use in Clinical Practice

Slides:



Advertisements
Similar presentations
New Insulin Formulations Guillermo Umpierrez, MD, FACP, FACE Professor of Medicine Emory University School of Medicine Part 1.
Advertisements

Insulin Initiation With NovoMix30
What's New in Basal Insulin for Diabetes
Recommendation In people with clinical cardiovascular disease in whom glycemic targets are not met, a SGLT2 inhibitor with demonstrated cardiovascular.
Short-, Intermediate-, Long-Acting Insulins
Diabetic Dyslipidemia in Practice
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Applying Data to Practice
New Guidelines to Prevent SCD: What You Need to Know
Applying Biosimilars in Hematologic Cancers
Special Consideration in Insulin Therapy
SGLT2 Inhibitors: What Do the Data Mean for My Patients?
Hyperkalemia in the Hospital: Collaboration to Improve Transitions of Care.
The Next Generation of Basal Insulins
Modern Strategies for Basal Insulin Use in T2D
Patient Case Discussions in T2D: What Intensification Plan Is Best?
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
What Comes Second?.
Patient-Centered Care in Cystic Fibrosis
How Early Should Basal Insulin Be Used in T2D Management?
Updates Abound.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
SGLT2 Inhibitors in the Modern Era: Why and Where?
Working as a Team for Improved Patient Outcomes in Type 2 Diabetes
Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.
Examining CV Effects of Basal Insulin Therapy
Applying Biosimilars in Oncology Practice: What Do You Need to Know?
Comparing Treatment Alternatives in Ankylosing Spondylitis
What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?
Innovative Insulin Combinations: A New strategy for the Person With T2DM.
Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.
Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?
Emerging Basal Insulins for Diabetes
Insights into Insulin Treatment Challenges: Real-World Evidence and Clinical Trial Data.
GLP-1 Receptor Agonists: How Early Is Appropriate?
What Is a Biosimilar?. Biosimilar Application in RA Clinical Practice: Current Knowledge and New Data  
Talking to Patients About Diabetes Management
Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?
Novel Basal Insulin Formulations in the Modern Era of T2D Management
Understanding Comparative Effectiveness Data in Psoriatic Arthritis
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
Exploring Statin Intolerance
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Simplifying Insulin Delivery for Better Patient Outcomes in T2D
Predictive Low Glucose Suspend (PLGS)
Novel Approaches to T1D Management
Patient-Centered Management in Pancreatic Cancer
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Better Diabetes Control With Novel Basal Insulins
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
Program. Basal Insulin in the Modern Era The CDE's Role in Improving Utilization and Outcomes.
Application of Biosimilars in RA IN Clinical Practice: Key Issues and Challenges  
Evaluating BTK Inhibitors in CLL
Insulin in Diabetes Management: Effective Patient Selection Is Key
COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?
Liraglutide Shows CV Benefit: Clinical Perspectives on the LEADER Trial
The Oncology Care Team.
The Role of Measurable Residual Disease in AML
ADA/EASD general recommendations for type 2 diabetes management (1).
Statin Selection in Patients With Pre-Diabetes: Case Considerations
Patient and Clinician Perspectives on Preventive Therapy for Migraine
What's New in Oral Combination Therapy for Type 2 Diabetes?
Practical Strategies for Overcoming Emotional Barriers to Insulin Initiation in the Primary Care Setting.
Fixed-Ratio Combination Therapy in T2DM
Emerging Basal Insulins for Diabetes
Biosimilars in Immune-Related Diseases
Fresh perspectives ON BASAL Insulins in diabetes care
The Challenge of Insulin Titration
Presentation transcript:

Improving Effective Basal Insulin Use in Clinical Practice

ADA Guideline Recommendations for Basal Insulin Use in T2D

Barriers to Insulin Use: Clinician-Level Factors

Barriers to Insulin Use: System-Level Factors

Barriers to Insulin Use: Patient-Level Factors

Communication Between Clinicians and Patients

Generics vs Biosimilars/Biologics

Follow-On Basal Insulin Therapy

Comparison of Follow-On Insulin With Traditional Insulin

Place of Follow-On Basal Insulin in Clinical Practice

Patient Opinion on Use of Biosimilar Insulin

Continued Role of NPH Insulin

Patient Communication: Switching From U100 Glargine to Follow-On Insulin Glargine U100

Experience With Biosimilar Glargine in Europe

Role of Basal Insulin in Type 2 Diabetes

Follow-On Basal Insulin Glargine in Insulin-Naive Patients

Follow-On Basal Insulin: Cost

Key Takeaways

Abbreviations